Enabling Novel Treatments for Nervous System Disorders by Improving Methods for Traversing the Blood–?Brain Barrier : Proceedings of a Workshop

Despite substantial advances in developing treatments for the serious illnesses that affect people worldwide, there remains a tremendous unmet need in the treatment of complex neurologic diseases, including neuropsychiatric and neurodegenerative disorders. Chief among the challenges that have hindered the development of therapeutics for central nervous system (CNS) disorders is the blood–brain barrier (BBB). The Forum on Neuroscience and Nervous System Disorders of the National Academies of Sciences, Engineering, and Medicine convened a workshop to explore the challenges associated with the BBB that have thus far stymied development of CNS drugs, examine new technologies that could address these challenges, and highlight potential opportunities for moving the field forward. This publication summarizes the presentations and discussions from the workshop. Table of ContentsFront Matter1 Introduction and Overview2 Traversing the BloodBrain Barrier: Challenges and Opportunities3 Modalities and Technologies for Brain Delivery4 Regulatory Considerations for Drugs That Traverse the BloodBrain Barrier5 Accelerating Research and Clinical Translation: Consortia and Public–Private PartnershipsAppendix A: ReferencesAppendix B: Workshop AgendaAppendix C: Registered Attendees

Despite substantial advances in developing treatments for the serious illnesses that affect people worldwide, there remains a tremendous unmet need in the treatment of complex neurologic diseases, including neuropsychiatric and neurodegenerative disorders. Chief among the challenges that have hindered the development of therapeutics for central nervous system (CNS) disorders is the blood–brain barrier (BBB). The Forum on Neuroscience and Nervous System Disorders of the National Academies of Sciences, Engineering, and Medicine convened a workshop to explore the challenges associated with the BBB that have thus far stymied development of CNS drugs, examine new technologies that could address these challenges, and highlight potential opportunities for moving the field forward. This publication summarizes the presentations and discussions from the workshop.